BRL-101

DRUG3 trials

Sponsors

Bioray Laboratories

Conditions

Beta-ThalassemiaSickle Cell Disease

Phase 1

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Active, not recruitingNCT05577312

Bioray LaboratoriesBeta-Thalassemia

Start: 2022-11-02End: 2027-07-10Updated: 2026-07-21

Unknown Phase

Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

Not yet recruitingNCT06287099

Bioray LaboratoriesSickle Cell Disease

Start: 2024-04-20End: 2026-05-10Target: 5Updated: 2024-03-19

Clinical Study of BRL-101 in Severe SCD

Enrolling by invitationNCT06300723

Bioray LaboratoriesSickle Cell Disease

Start: 2024-07-29End: 2026-06-15Target: 3Updated: 2024-07-31

Related Papers

Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia

Blood2023-11-0211 citations